

36th ENTIS Conference

11th – 14th
Sept 2025

ARISTOTLE UNIVERSITY'S
RESEARCH DISSEMINATION
CENTER (KEDEA)

THESSALONIKI, GREECE

Organized by



2nd OBSTETRICS
AND GYNECOLOGY
DEPARTMENT,
AUTH



ARISTOTLE
UNIVERSITY OF
THESSALONIKI

GREETINGS FROM THE ORGANIZERS	3-4
-------------------------------	-----

COMMITTEES	5
------------	---

INVITED SPEAKERS	6-7
------------------	-----

PROGRAM	9-17
---------	------

GENERAL INFORMATION	
---------------------	--

- CONGRESS	19
------------	----

- REGISTRATION	19
----------------	----

- SOCIAL EVENTS	20
-----------------	----

- THESSALONIKI	21
----------------	----

E-POSTERS	22-23
-----------	-------

NOTES	24-25
-------	-------



Dear colleagues, dear collaborators, dear friends,

we are looking forward to welcoming all of you to the ENTIS2025 conference, that will take place in Thessaloniki from the 11th to the 14th of September 2025, an event that aspires every year to bring together health professionals from different disciplines, offering a comprehensive scientific experience.

ENTIS2025, in true ENTIS tradition, is not just a conference; it is a platform for collaboration, knowledge and exchange of experiences. We invite you to make the most of this opportunity, participate in the discussions and actively contribute to shaping the future of science and medical practice. This year's program in its diversity, aims to cover the latest developments in reproductive toxicology, clinical teratology and their multiple related fields. Through high-level sessions, we will hopefully have the opportunity to examine innovative approaches, focus on practical solutions and promote holistic patient care.

Thank you very much for your participation - we wish you a constructive and creative conference.

On behalf of the Local Organizing Committee

Your host,

Chrysanthi Sardeli

MD, PhD, Associate Professor



On behalf of the ENTIS organization, we extend our warmest welcome to all participants joining us for ENTIS2025. We are deeply grateful to Dr. Chrysanthi Sardeli and the Local Organizing Committee for their exceptional dedication in bringing this year's conference to life in the magnificent city of Thessaloniki.

This year's diverse scientific program promises to advance our understanding across the full spectrum of reproductive toxicology and clinical teratology, fostering the interdisciplinary dialogue that defines the ENTIS tradition.

Beyond the scientific exchange, we are delighted that this gathering takes place in Thessaloniki, a city where ancient history meets vibrant modern culture, providing the perfect backdrop for both professional collaboration and meaningful social connections among colleagues from around the world.

We look forward to four days of outstanding science, enriching discussions, and the renewal of friendships that make our ENTIS community so special.

With warm regards,

Prof. Mati Berkovitch

ENTIS' President

ENTIS Board

Matitiah Berkovitch, President

TIS Zerifin, Clinical Pharmacology and Toxicology Unit, Shamir Medical Center (Assaf Harofeh), The Andy Lebach Chair of Clinical Pharmacology and Toxicology, Affiliated to the School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel Aviv, Israel

Sally Stephens, Vice-President

UK Teratology Information Service (UKTIS), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom of Great Britain and Northern Ireland

Marleen van Gelder, Treasurer

Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands

Orna Diav-Citrin

The Israeli Teratology Information Service, Department of Child Development and Rehabilitation, Ministry of Health, and the Hebrew University Hadassah Medical School, Jerusalem, Israel

Maria Ellfolk

Helsinki University Central Hospital – Teratology Information Service, Helsinki, Finland

Jorgos Eleftheriou

Poison Control Center and Teratology Information Center, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy

ENTIS Scientific Committee

Per Damkier, Chair

Department of Clinical Pharmacology, Odense University Hospital, Denmark; Department of Clinical Research, University of Southern Denmark, Denmark

Ken Hodson

UK Teratology Information Service (UKTIS), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom of Great Britain and Northern Ireland

Svetlana Shechtman

The Israeli Teratology Information Service, Department of Child Development and Rehabilitation, Ministry of Health, Jerusalem, Israel

Alice Panchaud

Service of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland

Brian Cleary

The Rotunda Hospital, Dublin and the School of Pharmacy, Royal College of Surgeons in Ireland, Dublin, Ireland

Matitiah Berkovitch

TIS Zerifin, Clinical Pharmacology and Toxicology Unit, Shamir Medical Center (Assaf Harofeh), The Andy Lebach Chair of Clinical Pharmacology and Toxicology, Affiliated to the School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel Aviv, Israel

Michael Ceulemans

Research Group Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium

Local Organising Committee

Chrysanthi Sardeli

Laboratory of Clinical Pharmacology, School of Medicine, Faculty of Health Sciences & Laboratory for the Study of Medical Law & Bioethics, Faculty of Law, Aristotle University of Thessaloniki

Dimitrios Kouvelas

Chair, Laboratory of Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki

Konstantinos Dinas

Chair, 2nd Department of Obstetrics & Gynecology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki

Stamatis Petousis

2nd Department of Obstetrics & Gynecology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki

Maria Fotoulaki

4th Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki

Kosmas Sarafidis

Chair, 1st Department of Neonatology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki

Dimitrios Zafeiriou

Chair, 1st Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki

36th ENTIS Conference

INVITED SPEAKERS



Professor
Alistair Boxall
BSc, PhD, Professor
Department of Environment and
Geography University of York, UK



Dr
Raffaella Buera
MD, Toxicologist
Poison Control Centre and Teratology
Information Service, Bergamo, Italy



Professor
Christina Chambers
Professor, San Diego, California, USA



Professor
Jakob Christensen
MD, PhD, Dr. Med. Sci., Professor
Consultant Neurologist, Consultant
Clinical Pharmacologist, Department of
Neurology, Aarhus University Hospital,
Aarhus, Denmark
Department of Clinical Medicine,
Aarhus University, Aarhus, Denmark



Dr
Nicholas Christofilidis
MD, MSc, FRCOG, Consultant Obstetrician,
Gynaecologist, Clinical and Scientific
Director Embryology Fertility Clinic,
Thessaloniki, Greece



Professor
Per Damkier
MD, PhD Professor,
Consultant Clinical Pharmacologist,
Department of Clinical Pharmacology,
Odense University Hospital, Denmark
Department of Clinical Research,
University of Southern Denmark,
Odense, Denmark



Professor
Paul Dargan
Professor of Clinical Toxicology
President of the European Association
of Poisons Centres and Clinical
Toxicologists Guy's and St Thomas



Dr
Georgios Eleftheriou
MD, MSc, PhD, 1st Assistant Clinical
Toxicologist Poison Control Centre and
Teratology Information Service,
Bergamo, Italy



Dr
Bénédicte Jacquemin
MD, MSc, PhD, Researcher
IRSET (Research Institute for
Environmental and Occupational Health),
INSERM, Rennes, France

INVITED SPEAKERS



Dr

Ken Hodson

MD, MRCP(UK), MRCOG, Consultant in Obstetrics and Maternal Medicine Royal Victoria Infirmary, Newcastle upon Tyne Hospitals, NHS Foundation Trust Head of UK Teratology Information Service (UKTIS)



Associate Professor

Line Kolding

MD, PhD, Associate Professor, Specialist in Gynecology and Obstetrics Department of Clinical Pharmacology & Department of Obstetrics and Gynecology, Aarhus University Hospital, Denmark Department of Clinical Medicine, Aarhus University, Denmark



Professor Dr.

Kristel van Calsteren

MD PhD, Professor, Specialist in Feto-Maternal Medicine Department of Obstetrics and Gynaecology, Division Feto-Maternal Medicine, University Hospital Leuven, Belgium Department of Development and Regeneration, Division Woman and Child, KU Leuven, Belgium



Professor

Georgios Mastorakos

MD, PhD, Professor, Consultant in Endocrinology 2nd Department of Obstetrics & Gynaecology, School of Medicine, Faculty of Health Sciences, National and Kapodistrian University of Athens, Greece



Professor

Hedvig Nordeng

Head of Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Norway



Associate Professor

Emmanouil Papanastasiou

MSc, PhD, Associate Professor, Medical Physicist Laboratory of Medical Physics & Digital Innovation, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece



Dr

Corinna Weber-Schoendorfer

MD, PhD
Pharmakovigilanz und Beratungszentrum für Embryonaltoxikologie, Charité – Universitätsmedizin Berlin, Berlin, Germany
Former Vice Head of TIS Berlin



Professor

Julie Werenberg Dreier

MSc, PhD, Professor
Department of Public Health, National Centre for Register-based Research, Aarhus University, Denmark



36th ENTIS Conference

11th – 14th
Sept 2025

ARISTOTLE UNIVERSITY'S
RESEARCH DISSEMINATION
CENTER (KEDEA)

THESSALONIKI, GREECE

THURSDAY 11th SEPTEMBER 2025

13:00–18:00 Registration Desk Open

Meeting Rooms 1 & 2, Mezzanine Floor

13:00–13:30 ENTIS Board

13:30–14:00 Scientific Committee Meeting

14:00–14:30 ENTIS–ConcePTION Steering Committee Meeting

14:30–15:00 ENTIS Digital (Website) Committee Meeting

15:00–15:30 Coffee Break

Auditorium I, Ground Floor

15:30–17:30 ENTIS Business Meeting

*Moderators: **Sally Stephens** & **Mati Berkovitch***

Auditorium I, Ground Floor

17:30–18:00 Lessons from the ConCEPTION Project & other Collaborative Research Projects

- Project ConcePTION

Dr Maya Berlin

Tel Aviv, Israel

- MADAM: Model Adjusted Doses for ALL Mothers

Miranda (MHM) van Tuyl

Noord-Brabant, Nederland

*Moderator: **Jonathan Luke Richardson***

18:00–21:00 Thessaloniki Tour

FRIDAY 12th SEPTEMBER 2025

08:30–17:30 Registration Desk Open

Auditorium I, Ground Floor

08:50–09:00 **Conference Opening**

Prof. Matitiahu Berkovitch, ENTIS President

Prof. Chrysanthi Sardeli, Welcome from the Local Organizing Committee-Housekeeping

Auditorium I, Ground Floor

09:00–10:30 **Paternal Exposures & reproductive outcomes (Round Table)**

- Paternal metformin and major congenital malformations: don't spook the horse

Professor Per Damkier

Odense, Denmark

- Paternal exposures & pregnancy outcomes – the case of valproate

Professor Jakob Christensen

Aarhus, Denmark

- Effect of paternal MTX exposure on male fertility and birth outcomes. What is known so far?

Dr Corinna Weber-Schoendorfer

Berlin, Germany

Moderator: **Marleen van Gelder**

10:30–11:00 **Coffee break**

Auditorium I, Ground Floor

11:00–11:45 **Risk Assessment of Medicinal Products on Human Reproduction and Lactation: from Data to Labelling**

Dr Raffaella Butera

Pavia/Bergamo, Italy

Moderator: **Alice Panchaud**

FRIDAY 12th SEPTEMBER 2025

Mezzanine Floor

11:45–13:00 Poster Session

Posters Presentations 1 to 33

**Titles on page 22*

Moderators: **Brian Cleary** & **Jonathan Luke Richardson**

13:00–14:00 Lunch break

Auditorium I, Ground Floor

14:00–16:00 Human reproduction and the environment (Round Table)

- Outdoor air pollution effects on fertility and pregnancy outcomes: an epidemiological approach

Dr Bénédicte Jacquemin

INSERM, France

- Natural and medical ionizing radiation effects on human fertility and pregnancy

Dr Emmanouil Papanastasiou

Thessaloniki, Greece

- Pharmaceuticals and other contaminants in the aquatic and non-aquatic environment

Professor Alistair Boxall

York, UK

- Endocrine disruptors & their effects on human reproduction

Professor Georgios Mastorakos

Athens, Greece

Moderators: **Benoit Marin** & **Herbert Juch**

16:00–16:30 Coffee break

FRIDAY 12th SEPTEMBER 2025

Auditorium I, Ground Floor

16:30–17:15 **Prenatal Folate Supplementation – Is there a risk for increased incidence of childhood cancer?**
Professor Julie Werenberg Dreier
Aarhus, Denmark
*Moderator: **Mine Kadioğlu-Duman***

Auditorium I, Ground Floor

17:15–18:00 **OTIS Lecture**
Studies of OTIS/Mother-to-baby: an update
Professor Christina Chambers
San Diego, California, USA
*Moderator: **Orna Diav-Citrin***

Place: Tellogleion Foundation of Arts

20:00–22:00 **Welcome Reception**

SATURDAY 13th SEPTEMBER 2025

08:30–17:30 Registration Desk Open

Auditorium I, Ground Floor

09:00–10:30

- Neonatal abstinence syndrome: an update

Dr. Georgios Eleftheriou

Bergamo, Italy

- Recreational drug toxicity in Europe: insights from the Euro-DEN Plus Project

Professor Paul I. Dargan

President of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), London, UK

*Moderators: **Alessandra Pistelli** & **Marco de Santis***

10:30–11:00 Coffee break

Auditorium I, Ground Floor

11:00–11:45

Taking a nuanced approach to biologics in pregnancy (State of the Art Lecture)

Dr Ken Hodson

Newcastle upon Tyne, UK

*Moderator: **Miranda van Tuyl***

Auditorium I, Ground Floor

11:45–12:15

Test yourself in clinical teratology Quiz

Professor Orna Diav-Citrin & Dr Svetlana Shechtman

Jerusalem, Israel

12:15–13:15 Lunch break

13:15–13:45 Walk & Talk

SATURDAY 13th SEPTEMBER 2025

Mezzanine Floor

13:45–14:40 Poster Session

Posters Presentations 34 to 66

**Titles on page 22*

Moderators: **Judith Cottin & Debra Kennedy**

Auditorium I, Ground Floor

14:40–16:00 Oral Communications

- 14:40–14:50 **OP1. Pregnancy outcomes associated with first trimester exposure to direct oral anticoagulants: a cohort study**
Bénédicte Coulm
- 14:50–15:00 **OP2. mRNA COVID-19 vaccination in pregnancy and risk of pregnancy loss: a progressive multistate model to account for time-dependent exposure**
Evelin Beck
- 15:00–15:10 **OP3. Papaverine Use during Pregnancy: Findings from a Large Population-Based Cohort Study**
Sharon Daniel
- 15:10–15:20 **OP4. Isotretinoin exposure during pregnancy: a population-based study from Finland**
Maria Ellfolk
- 15:20–15:30 **OP5. Clinical and immunologic evaluation of infants with fetal exposure to immunomodulatory biological agents**
Karin Nilsson
- 15:30–15:40 **OP6. Prescription-based drug use of acetaminophen among pregnant women in Denmark from 2000–2023: A Drug Utilization Study**
Erika B. Gram
- 15:40–15:50 **OP7. Designing patient information about medicine use in pregnancy for patients from ethnically marginalised groups**
Amanda Greenall

Moderators: **Maya Berlin & Maria Ellfolk**

SATURDAY 13th SEPTEMBER 2025

16:00–16:30 Coffee break

Auditorium I, Ground Floor

16:30–17:15 **ADHD/ADD medications in pregnancy & lactation** (state of the art lecture)

Professor Hedvig Nordeng

Oslo, Norway

Moderator: **Veronique Maas**



Angela Lupattelli - In memoriam

THE MET HOTEL SKY BAR - RESTAURANT

20:00–23:00 Conference Dinner

SUNDAY 14th SEPTEMBER 2025

09:30–15:00 Registration Desk Open

Auditorium I, Ground Floor

09:30–11:00

- Fertility preservation prior to exposure to antineoplastic and other medicines. What is the evidence and what are the consequences to health care systems (State of the Art Lecture)

Dr Nicholas Christoforidis

Thessaloniki, Greece

- Treatment of cancer during pregnancy: considerations on the use of antineoplastic agents

Professor Dr Kristel Van Calsteren

Leuven, Belgium

Moderators: Corinna Weber-Schoendorfer & Michael Ceulemans

11:00–11:30 Coffee break

Auditorium I, Ground Floor

11:30–12:30

Oral communications

- 11:30–11:40 **OP8. Poor neonatal adaptation after exposure to serotonergic antidepressants during the second or third trimester**

Maarit K Leinonen

- 11:40–11:50 **OP9. Acetaminophen use during pregnancy and the risk of neurodevelopmental disorders in childhood: A Meta-analysis**

Judith Cottin

- 11:50–12:00 **OP10. When Caution Becomes Harmful: Regulatory Overreach in Pregnancy and Lactation During Labeling Across Global Authorities**

Omer Cohen

- 12:00–12:10 **OP11. In utero exposure to acetazolamide and pregnancy outcomes: a cohort study**

Camille Reinaud

- 12:10–12:20 **OP12. Exposure during pregnancy to IL-1 targeted therapies**

Benoit Marin

Moderators: Svetlana Shechtman & Stephanie Padberg

SUNDAY 14th SEPTEMBER 2025

Auditorium I, Ground Floor

12:30-13:00

The real-time data system FREIA: a new approach for drug safety in pregnancy

Professor Line Kolding

Aarhus, Denmark

Dr Jakob Henriksen

Aarhus, Denmark

*Moderators: **Mati Berkovitch - Chrysanthi Sardeli***

13:00-13:30 Meeting end - Farewell

13:30-14:30 Lunch break

CONGRESS INFORMATION

Congress Venue

Aristotle University's Research Dissemination Center (KEDEA)
Address: Tritis Septemvriou Str. at Aristotle University's campus (between the Student Club and the University Gymnasium)
Postcode: 546 36, Thessaloniki, Greece / Phone: (+30) 2310 994013

Congress Dates

Thursday 11th September 2025
Friday 12th September 2025
Saturday 13th September 2025
Sunday 14th September 2025

Congress Language

The official language of the congress is English. No simultaneous translation will be provided.

Congress Website

www.36entis2025.com

Accommodation

A number of rooms have been provisionally reserved at Thessaloniki. For information about accommodation, please contact the Conference Organization Office.

Climate & Clothing

The weather in Thessaloniki in September is warm and sunny, so regular summer clothing is usually sufficient. It's wise to pack a light jacket for evening outings and comfortable shoes for walking. Check the weather forecast before you travel to be prepared.

Currency & Payments

The currency in Greece is the Euro (EUR). Credit cards are widely accepted. ATMs are readily available throughout the city.

Electricity

Greece uses Type C and F sockets with a standard voltage of 230V and a frequency of 50Hz. If you're coming from a country with different plug types, don't forget to bring an adapter.

Emergency Contacts

Emergency Number: Dial 112 for police, ambulance, or fire services. Hospitals in Thessaloniki take turns every 24 hours at receiving emergency cases, so please contact the personnel manning the registration desk or your host if you need to visit one. You do not need a physician's referral to visit the Emergency Department in Greek hospitals.

Health & Wellness

Tap water and street food in Greece is of high quality and safe to drink or eat. Pharmacies are available for any over-the-counter needs daily, but in case of an emergency or if you require a prescription issued, please contact the personnel manning the registration desk or your host.

Language

Greek is the official language, but English is spoken and understood by most locals. You'll find that most Greeks, especially younger ones, are fluent in English and happy to assist visitors.

Local Etiquette

Greeks are known for their hospitality and exuberance. When greeting someone you know well, a light hug and kiss on each cheek is customary, however in more professional settings saying hello and a firm handshake are more than enough. Punctuality is not a top priority for most Greeks, so please allow for some minor delays "when in town" but for all conference sessions and appointments the utmost punctuality will be observed. While tipping is appreciated, it is not obligatory. If you decide to tip, coins or banknotes are most welcome.

GENERAL INFORMATION

Safety & Security

Greece is considered a safe country for tourists and locals alike. Thessaloniki, like the rest of Greece, is known for its low crime rates and friendly atmosphere. It's safe to walk around alone, even in the evenings, so feel free to explore the city and enjoy the local culture.

Transportation

One can not claim that Thessaloniki boasts a completely efficient public transport system, but the Metro is up and running ("Panepistimio" Station is located 50m from the meeting venue and most hotels where rooms are available for booking are within walking distance from the other Metro Stations) and taxis (which you can flag down on the street or hire from the designated Taxi Stops all around the city) are an affordable and efficient means of transportation. To get to and from the Thessaloniki Airport MAKEDONIA, you may either use a bus or a taxi. More information is available here: <https://www.skg-airport.gr/en/flights--more/airport-information>. The city centre is pedestrian-friendly, so walking is often the best way to explore. If you're traveling outside of Thessaloniki, please contact the personnel manning the registration desk for information and help booking your trip.

REGISTRATION

	Early Bird up to 30 th June 2025	Regular / On Site 1 st July 2025
ENTIS Members	550 €	650 €
ENTIS Member Students	450 €	650 €
OTIS Members / EAPCCT	600 €	650 €
OTIS Member Students / EAPCCT	500 €	650 €
Non-Members	650 €	650 €
Non-Member Students	550 €	650 €
One Day Attendance	200 €	200 €
Student Definition: * Currently enrolled as a MSc or PhD Student		
Conference Dinner	80 €	80 €

Registration fee covers

- Venue facilities, utilities
- Welcome Reception - Friday 12th September 2025 evening
- Coffee Breaks and Light Lunches according to the program
- Water & fruit available throughout the Conference
- City Tour - Thursday 11th September 2025 - **included, reservation needed**
- Conference Dinner Saturday 13th September 2025 - **not included**

Refund policy:

For those that have paid the registration fee but are unable to attend, a refund may be requested. Requests made before May 31st, 2025: 75% of the registration fee will be refunded. Requests made after June 1st, 2025: No refunds will be provided.

Payment:

All payments are to be made in EUR (€) without charges for the beneficiary, to the order of **VOYAGER TRAVEL & CONGRESS** as follows. Bank charges are to be settled by the payer. Confirmation of services and payment invoices will be sent after receipt of the appropriate fees by e-mail to the address provided for communication. Late registration fees will apply for any payments received after the stated deadline. Outstanding payments are to be paid onsite. Early bird rates are valid if paid until the early bird registration deadline.

SOCIAL EVENTS

Thessaloniki Tour

Discover the most famous landmarks of Thessaloniki, a city built 2.300 years ago!

The guided tour will take place on Thursday 11 September 2025.

Begins at 18:00 at Aristotle University's Research Dissemination Center (KEDEA) – Congress Venue and ends at 21:00 at Aristotelous Square, in the city center.

Welcome Reception

The 36th ENTIS **Welcome Reception** will take place on the **12th of September, at 20:00 pm.**

Place: Tellogleion Foundation of Arts (*Address: AUTH 159A Agiou Dimitriou str. 54636 Thessaloniki*)

There is no Fee for delegates to attend

OFFICIAL WELCOME RECEPTION TIMETABLE

20:00 pm
Arrival

22:00 pm
Departure

Official Conference Dinner

The 36th ENTIS Conference Official Dinner will take place on the **13th of September**, at the rooftop of the **THE MET HOTEL SKY BAR – RESTAURANT**, at **20:00pm**

A ticket to the dinner costs **80€/person** and reservations can be made through the registration form. For last minute attendees a limited number of tickets will also be available during the Conference through the registration desk.

The price includes:

- Full menu and drinks
- Transfer by private bus to and from the dinner venue

OFFICIAL DINNER TIMETABLE

19:30 pm

Departure from the proposed conference hotels

20:00 – 23:00 pm

Dinner at "SKY BAR & RESTAURANT" MET HOTEL

23:00 pm

Departure to the proposed conference hotels

Please let us know about any allergies or menu preferences (meat/fish/vegetarian options will be available)

GENERAL INFORMATION

THESSALONIKI


The City

Thessaloniki has many stories to tell, starting by the moment of its foundation in 316/315 B.C. Greece's second major economic, industrial, commercial and political center, and a major transportation hub for the rest of southeastern Europe. The city is renowned for its festivals, events and vibrant cultural life in general, and is considered to be Greece's cultural capital. Thessaloniki is just half an hour distance from the seaside and an hour away from Mount. Olympus!

More information: <https://thessaloniki.travel/>

Travel to Thessaloniki

The International Airport "Macedonia" (SKG) connects Thessaloniki with approximately 31 countries and more than 60 foreign cities with direct flights, as well as 35 cities and islands in Greece. The direct flights from/to Thessaloniki are Vienna, Rome, Frankfurt, Dusseldorf, Munich, Stuttgart, Belgrade, Bucharest, London and Moscow.



Connectivity

Thessaloniki's International Airport is located only 14km away from the city center. Each year the connectivity network is expanding and more international and domestic flights are connecting Thessaloniki with destinations all over the world. The enhancement changes implemented at the Airport are creating a new era at Greece's 2nd largest city. Modern and smarter after an extensive renovation, Thessaloniki Airport opened its doors in Feb 2021 expanded, fresh and modernized. The program included a new terminal and increased number of check-ins, security lanes and departure gates.

P1. Pragmatic and Contextualized Methods Selection for Safety Assessment of Infant Systemic Exposure Through Human Milk: The Milk4baby Decision Tree
Anaëlle Monfort

P2. Developing a Search Strategy to Assess Safety of Medications during Pregnancy and Lactation
Elizabeth Uleryk

P3. The use of risk medication during pregnancy: data from the Dutch Pregnancy Drug Register
Veronique Y.F. Maas

P4. Intravitreal Aflibercept Exposure During Early Pregnancy: Analysis of two cases
Aylin Toplu

P5. Training Strategies for Caregivers of Adults with Neurological Disorders: Integrating Occupational Therapy and Psychological Support
Myrto Patagia Bakaraki

P6. Evaluation of exposures of glucagon-like peptide-1 receptor agonists during pregnancy: Case series from a university's teratology information service
Berna Özen

P7. Sibling and non-sibling designs in studies investigating the risk of drug exposure during pregnancy: same results? A preliminary meta-epidemiological study
Cyndie Picot

P8. First trimester exposure to piracetam: A report of four cases
Deniz Karagülle

P9. Hypersensitivity reactions to parenteral iron in pregnant women and fetal consequences
Emilie Vittaz

P10. Retrospective study on drug exposure during pregnancy and associated neonatal outcomes in mothers with cardiac diseases
Emmanuel Gachiniard

P11. High dose ulipristal exposure in the first trimester: a case report
Ersan Horoz

P12. Cognitive development in children exposed to maternal treatment with selective serotonin reuptake inhibitors during pregnancy and breastfeeding
Essi Whaites Heinonen

P13. Evaluation of prenatal exposures in congenital heart defects in Rio Grande do Sul, Brazil
Fabyanne G. de Oliveira

P14. ADHD During Pregnancy and the First Postpartum Year– A Survey Among Norwegian Women
Gro C. Havnen

P15. High-dose Vitamin D Eggs in Norway: Coordinated Response and Guidance for Pregnant and Breastfeeding Women
Gro C. Havnen

P16. Associations Between Maternal Prepregnancy Body Mass Index and Maternal and Cord Blood Metabolome
Heidi K. Sormunen-Harju

P17. Lisdexamfetamine use during lactation – Clinical follow-up of 17 exposed infants
Ingrid Alvarez

P18. Understanding Real-World Concerns and Information Needs on Medication Use During Pregnancy and Lactation in Japan: A Web-Based Survey to Support Future Evidence Generation
Izumi Fujioka

P19. Lyell syndrome in pregnancy: A case report
Georgios Eleftheriou

P20. New Frontiers in Clinical Toxicology. The connection through toxicology and teratology
Georgios Eleftheriou

P21. Ocrelizumab use before pregnancy and neonatal B-cell depletion. A case report
Georgios Eleftheriou

P22. The Use of Newly Marketed Drugs During Pregnancy and Lactation: The FARVIGRAL Project
Georgios Eleftheriou

P23. Benzodiazepines exposure during pregnancy: systematic review and meta-analysis of observational studies
Judith Cottin

P24. A multidisciplinary Consultation Meeting for the Management of Pregnant or Pregnancy-Planning Epileptic Patients
Judith Cottin

P25. Acceptance, comprehensibility and impact of embryotox.de in routine healthcare
Katarina Dathe

P26. Oropouche (Sloth) Fever as a possible new human teratogen
Lavinia Schuler-Faccini

P27. Association between in utero exposure to acetaminophen and external genital tract malformations in boys and girls: a systematic review and meta-analysis
L. Eletri

P28. The information system FREIA, a unique work tool to optimize fetal drug safety during pregnancy
Line Kolding

P29. An exploratory linkage and disproportionality analysis of national congenital anomaly and primary care dispensing data in the UK
Jonathan L. Richardson

P30. Exposure to monoclonal antibodies during pregnancy and lactation – a growing concern
Maja Ratajczak-Enselme

P31. Leflunomide exposure in pregnancy: always some uncertainty, a case report that raises questions
Marie-Andrée Thompson-Bos

P32. Descriptive Analysis of Folate Supplementation Patterns and RBC Folate Levels in Women of Reproductive Age in a Brazilian Hospital
Marília K. Rockenbach

P33. Asthma medication use before and during pregnancy: guidelines versus multinational practice
Marleen M.H.J. van Gelder

P34. Maternal high therapeutic dose of iodide during breastfeeding: results from the UmbrelLACT study – A contribution from the ConcePTION project
Martje Van Neste

P35. Tacrolimus exposure in human milk: case series from the UmbrellACT study – A contribution from the ConCEPTION project
Martje Van Neste

P36. High Dose Estrogen During Breastfeeding – A Prospective Study
Shira Shalit

P37. Ropradine during breastfeeding: Two case reports
Shira Shalit

P38. A Case Report: Niclosamide and albendazole use during the first trimester of pregnancy
Mert Kaşkal

P39. Pregnancy outcome following exposure to ergotamine tartrate combinations exposure: Preliminary results of 26 cases
Mesut Güngör

P40. Alcohol, tobacco and illicit drug use before and during pregnancy in Belgium between 2022-2024
Sien Lenie

P41. Pregnancy and infant outcomes following prenatal exposure to brivaracetam: a multinational case series from Belgium, the Netherlands and UK
Michael Ceulemans

P42. Pregnancy outcome following exposure to vaginal fenticonazol in pregnancy: a case report
Michael Ceulemans

P43. Feasibility of the long term data collection on infant development in the BELpREG registry in Belgium
Michael Ceulemans

P44. Prevalence and type of paternal medication used in the preconception period in Belgium
Michael Ceulemans

P45. Prevalence and type of potential teratogenic medications prescribed to hospitalized pregnant women in Belgium
Michael Ceulemans

P46. Medication adherence during and after pregnancy among women at risk for gestational hypertensive disorders
Pauline Dreesen

P47. Physicians' perceptions toward drug administration in pregnancy and package inserts: A qualitative study
Mikako Goto

P48. Safety of azathioprine and methylprednisolone during breastfeeding: A Case Report
Busra Demirci

P49. Safety of liraglutid during pregnancy: A Case Report
Hakan Ozdemir

P50. The use of azathioprine and mercaptopurine during pregnancy is associated with an increased risk of intrahepatic cholestasis of pregnancy
Miranda van Tuyl

P51. Pregnancy and infant outcomes following the use of asthma medicines with an unknown risk classification
Veronique Y.F. Maas

P52. Do women experience an increase in milk supply after use of over-the-counter and prescribed galactagogues?
Petra Woestenber

P53. Increased risk of mood disorders associated with metoclopramide treatment for nausea and vomiting during pregnancy
Veronique Y.F. Maas

P54. Treatment of Meniere's disease with betahistine in the first trimester of pregnancy
Veronique Y.F. Maas

P55. Perinatal Mental Health Issues in Breastfeeding Consultations: Insights from the Japan Drug Information Institute in Pregnancy (J-TIS)
Sachi Koinuma

P56. Pseudoephedrine use during Pregnancy and the risk for Major congenital malformations: A Large Population-Based Cohort Study
Saar Dor

P57. The effect of combined contraceptives during breastfeeding on lactation, mothers, and infants-network meta-analysis
Shira Shalit

P58. Is the use of mesalazine during pregnancy at concern for the fetal kidneys?
Corinne Simon

P59. Agomelatine exposure during pregnancy: An Australian Observational Cohort Study
Susan Kwok

P60. Assessing Large Language Models in Clinical Teratology: Preliminary Findings from a Multi-Model Performance Analysis
Yusuf Cem Kaplan

P61. Register data on neonatal symptoms added to the Swedish knowledge base Janusmed Drugs and Birth Defects
Ulrika Nörby

P62. Pregnancy-related Adverse Drug Reactions with JAK inhibitors: A Pharmacovigilance Disproportionality Analysis using VigiBase
Nazanin Abolhassani

P63. Medication use in pregnant women with Polycystic Ovary Syndrome (PCOS): A nationwide cohort study from The Netherlands
Geranne L.G. Jiskoot

P64. The MediMama app – the successful implementation of a Dutch mobile app on the safety of over-the-counter medicines during pregnancy and breastfeeding
Veronique Y.F. Maas

P65. Safety of aripiprazole in first trimester pregnancy: a prospective cohort study
Cecilia Lanzi

P66. CGRP monoclonal antibodies for migraine and the risk of adverse pregnancy outcomes: Women's Headache Health – a nationwide registry-based cohort study from 2018 to 2022
Bettina Riedel

NOTES

NOTES



36th ENTIS Conference

11th – 14th
Sept 2025

ARISTOTLE UNIVERSITY'S
RESEARCH DISSEMINATION
CENTER (KEDEA)

THESSALONIKI, GREECE